Alzamend Neuro, Inc. (ALZN)
ALZN Stock Price Chart
Explore Alzamend Neuro, Inc. interactive price chart. Choose custom timeframes to analyze ALZN price movements and trends.
ALZN Company Profile
Discover essential business fundamentals and corporate details for Alzamend Neuro, Inc. (ALZN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Jun 2021
Employees
4.00
Website
https://www.alzamend.comCEO
Stephan Jackman
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
ALZN Financial Timeline
Browse a chronological timeline of Alzamend Neuro, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 10 Sept 2025
EPS came in at -$2.36 surpassing the estimated -$3.69 by +36.04%.
Stock split effective on 12 May 2025
Shares were split 1 : 9 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Apr 2025
EPS came in at -$1.46 .
Earnings released on 10 Mar 2025
EPS came in at -$1.71 surpassing the estimated -$2.61 by +34.48%.
Earnings released on 11 Dec 2024
EPS came in at -$3.60 surpassing the estimated -$21.42 by +83.19%.
Earnings released on 11 Sept 2024
EPS came in at -$11.25 falling short of the estimated -$2.38 by -372.69%.
Earnings released on 30 Jul 2024
EPS came in at -$13.35 falling short of the estimated -$2.75 by -385.45%, while revenue for the quarter reached $76.11K .
Stock split effective on 16 Jul 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 25 Mar 2024
EPS came in at -$34.20 falling short of the estimated -$0.32 by -10.59K%.
Earnings released on 15 Dec 2023
EPS came in at $39.60 surpassing the estimated -$0.67 by +6.01K%.
Stock split effective on 31 Oct 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Sept 2023
EPS came in at -$53.98 falling short of the estimated -$47.23 by -14.29%.
Earnings released on 27 Jul 2023
EPS came in at -$40.48 falling short of the estimated -$30.36 by -33.33%.
Earnings released on 15 Mar 2023
EPS came in at -$0.06 falling short of the estimated -$0.04 by -50.00%.
Earnings released on 12 Dec 2022
EPS came in at -$0.03 falling short of the estimated -$0.02 by -25.00%.
Earnings released on 13 Sept 2022
EPS came in at -$0.03 surpassing the estimated -$0.07 by +57.14%.
Earnings released on 19 Jul 2022
EPS came in at -$0.04 falling short of the estimated -$0.03 by -33.33%.
Earnings released on 15 Mar 2022
EPS came in at -$0.03 falling short of the estimated -$0.02 by -50.00%.
Earnings released on 13 Dec 2021
EPS came in at -$0.04 falling short of the estimated -$0.03 by -60.00%.
Earnings released on 13 Sept 2021
EPS came in at -$0.84 .
Earnings released on 29 Jul 2021
EPS came in at -$0.51 .
Earnings released on 31 Jan 2021
EPS came in at -$0.46 .
Earnings released on 31 Oct 2020
EPS came in at -$0.56 .
ALZN Stock Performance
Access detailed ALZN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.